NASDAQ:PTX - Pernix Therapeutics Stock Price, Price Target & More

$2.33 +0.02 (+0.87 %)
(As of 04/25/2018 12:24 PM ET)
Previous Close$2.31
Today's Range$2.28 - $2.39
52-Week Range$2.00 - $7.15
Volume24,925 shs
Average Volume124,123 shs
Market Capitalization$28.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56

About Pernix Therapeutics (NASDAQ:PTX)

Pernix Therapeutics logoPernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PTX
CUSIP71426V10
Phone800-793-2145

Debt

Debt-to-Equity Ratio-1.61%
Current Ratio1.00%
Quick Ratio0.94%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.07 million
Price / Sales0.19
Cash FlowN/A
Price / CashN/A
Book Value($14.77) per share
Price / Book-0.16

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-77,140,000.00
Net Margins-52.81%
Return on EquityN/A
Return on Assets-39.22%

Miscellaneous

Employees171
Outstanding Shares11,870,000

How to Become a New Pot Stock Millionaire

Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions

What is Pernix Therapeutics' stock symbol?

Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX."

How were Pernix Therapeutics' earnings last quarter?

Pernix Therapeutics Holdings (NASDAQ:PTX) posted its earnings results on Thursday, March, 8th. The specialty pharmaceutical company reported ($2.78) EPS for the quarter. The specialty pharmaceutical company earned $41.54 million during the quarter. View Pernix Therapeutics' Earnings History.

When is Pernix Therapeutics' next earnings date?

Pernix Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Pernix Therapeutics.

Who are some of Pernix Therapeutics' key competitors?

Who are Pernix Therapeutics' key executives?

Pernix Therapeutics' management team includes the folowing people:
  • John A. Sedor, Chairman of the Board, Chief Executive Officer (Age 72)
  • Angus Smith, Senior Vice President, Chief Business Officer and Principal Financial Officer
  • Kenneth Robert Pina, Senior Vice President, Chief Compliance Officer, General Counsel (Age 59)
  • Glenn Whaley, Interim Vice President - Finance, Principal Accounting Officer, Corporate Controller (Age 49)
  • John R. Leone, Lead Independent Director (Age 68)
  • Douglas J. Swirsky, Director (Age 48)
  • Dennis H. Langer M.D. J.D., Independent Director (Age 66)
  • Gabriel S. Leung, Independent Director (Age 55)

Has Pernix Therapeutics been receiving favorable news coverage?

Headlines about PTX stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pernix Therapeutics earned a media sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 47.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Pernix Therapeutics?

Shares of PTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pernix Therapeutics' stock price today?

One share of PTX stock can currently be purchased for approximately $2.33.

How big of a company is Pernix Therapeutics?

Pernix Therapeutics has a market capitalization of $28.02 million and generates $146.07 million in revenue each year. Pernix Therapeutics employs 171 workers across the globe.

How can I contact Pernix Therapeutics?

Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected]


MarketBeat Community Rating for Pernix Therapeutics (PTX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  454
MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pernix Therapeutics (NASDAQ:PTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Pernix Therapeutics (NASDAQ:PTX) Consensus Price Target History

Price Target History for Pernix Therapeutics (NASDAQ:PTX)

Pernix Therapeutics (NASDAQ:PTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Pernix Therapeutics (NASDAQ:PTX) Earnings History and Estimates Chart

Earnings by Quarter for Pernix Therapeutics (NASDAQ:PTX)

Pernix Therapeutics (NASDAQ PTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018N/AView Earnings Details
3/8/2018Q4 2017($2.78)$41.54 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.57)$40.47 millionViewN/AView Earnings Details
7/27/2017Q2 2017($4.40)($2.16)$34.32 millionViewN/AView Earnings Details
5/15/2017Q1 2017($4.80)($2.94)$29.74 millionViewN/AView Earnings Details
3/28/2017Q4 2016($3.86)$30.17 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.60)($2.99)$48.60 million$41.50 millionViewN/AView Earnings Details
8/11/2016Q2($0.08)($0.47)$46.98 million$36.75 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.42)$44.55 million$32.50 millionViewN/AView Earnings Details
3/10/2016Q4$0.01($0.59)$47.95 million$46.37 millionViewListenView Earnings Details
11/5/2015Q315$0.01$0.08$46.83 million$48.60 millionViewN/AView Earnings Details
8/6/2015Q215($0.01)($0.10)$50.70 million$47.00 millionViewN/AView Earnings Details
5/1/2015Q115$0.04($0.11)$34.55 million$33.90 millionViewN/AView Earnings Details
2/25/2015Q414$0.18$0.25$52.70 million$53.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.02)$28.10 million$31.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.05)($0.16)$26.20 million$17.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.26)$23.65 million$19.10 millionViewN/AView Earnings Details
3/17/2014Q413($0.10)($0.15)$23.82 million$23.90 millionViewN/AView Earnings Details
11/12/2013Q3($0.1250)($0.16)$23.06 million$18.30 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.13)($0.16)$20.82 million$20.60 millionViewN/AView Earnings Details
5/10/2013Q1 2013$0.02($0.05)$27.56 million$22.08 millionViewN/AView Earnings Details
3/18/2013Q4 2012$0.60($0.30)ViewN/AView Earnings Details
11/14/2012Q312$0.03($0.01)$15.04 million$18.10 millionViewN/AView Earnings Details
8/14/2012Q2 2012$0.10($0.33)ViewN/AView Earnings Details
5/15/2012Q1 2012$0.90$0.45ViewN/AView Earnings Details
3/28/2012Q4 2011$1.40$1.61ViewN/AView Earnings Details
11/15/2011Q3 2011$0.60$0.79ViewN/AView Earnings Details
8/16/2011Q2 2011$0.40$0.65ViewN/AView Earnings Details
5/17/2011Q1 2011$1.20$0.68ViewN/AView Earnings Details
3/31/2011Q4 2010$1.40$0.66ViewN/AView Earnings Details
11/12/2010Q3 2010$0.30$0.74ViewN/AView Earnings Details
8/16/2010Q2 2010$0.10ViewN/AView Earnings Details
5/17/2010Q1 2010$2.41ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pernix Therapeutics (NASDAQ:PTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pernix Therapeutics (NASDAQ PTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 17.05%
Insider Trading History for Pernix Therapeutics (NASDAQ:PTX)
Insider Trading History for Pernix Therapeutics (NASDAQ:PTX)

Pernix Therapeutics (NASDAQ PTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2016Robert Bruce ReillyInsiderSell155,000$0.06$9,300.00
11/4/2016Robert Bruce ReillyInsiderSell45,000$0.07$3,150.00
8/19/2015Sanjay S PatelCFOBuy5,000$4.60$23,000.007,000View SEC Filing  
8/18/2015Douglas DrysdaleCEOBuy8,500$4.69$39,865.0095,161View SEC Filing  
5/6/2015Douglas DrysdaleCEOBuy16,000$6.40$102,400.00View SEC Filing  
5/6/2015Sanjay S PatelCFOBuy2,000$6.42$12,840.00View SEC Filing  
11/3/2014Tracy Simmons CliffordInsiderSell2,246$10.00$22,460.00View SEC Filing  
10/28/2014Tracy Simmons CliffordInsiderSell12,754$10.00$127,540.00View SEC Filing  
5/21/2014James Edward Jr. Smithmajor shareholderSell194,600$6.13$1,192,898.003,498,504View SEC Filing  
5/16/2014James Edward Jr. Smithmajor shareholderSell310,200$6.12$1,898,424.003,693,104View SEC Filing  
5/14/2014James Edward Jr. Smithmajor shareholderSell289,400$5.47$1,583,018.004,003,304View SEC Filing  
5/9/2014James Edward Jr. Smithmajor shareholderSell45,000$4.37$196,650.004,292,704View SEC Filing  
5/6/2014James Edward Jr. Smithmajor shareholderSell45,000$4.44$199,800.004,337,704View SEC Filing  
5/1/2014James Edward Jr. Smithmajor shareholderSell30,000$4.68$140,400.004,382,704View SEC Filing  
4/29/2014James Edward Jr. Smithmajor shareholderSell30,000$4.88$146,400.004,412,704View SEC Filing  
4/25/2014James Edward Jr. Smithmajor shareholderSell30,000$5.20$156,000.004,442,704View SEC Filing  
4/24/2014James Edward Jr. Smithmajor shareholderSell30,000$4.94$148,200.004,472,704View SEC Filing  
4/17/2014James Edward Jr. Smithmajor shareholderSell20,000$4.35$87,000.004,502,704View SEC Filing  
4/15/2014James Edward Jr. Smithmajor shareholderSell45,000$4.63$208,350.004,522,704View SEC Filing  
4/10/2014James Edward Jr. Smithmajor shareholderSell45,000$5.03$226,350.004,567,704View SEC Filing  
4/7/2014James Edward Jr. Smithmajor shareholderSell45,000$4.90$220,500.004,612,704View SEC Filing  
4/2/2014Cooper CollinsInsiderSell90,000$5.26$473,400.002,500,046View SEC Filing  
4/2/2014James Edward Jr. Smithmajor shareholderSell45,000$5.26$236,700.004,657,704View SEC Filing  
3/28/2014James Edward Jr. Smithmajor shareholderSell45,000$5.47$246,150.004,702,704View SEC Filing  
3/25/2014James Edward Jr. Smithmajor shareholderSell255,000$4.21$1,073,550.004,747,704View SEC Filing  
3/4/2014Cooper CollinsInsiderSell3,590,000$3.40$12,206,000.002,590,046View SEC Filing  
2/5/2014Cooper Collinsmajor shareholderSell90,000$2.22$199,800.006,180,046View SEC Filing  
1/7/2014Cooper Collinsmajor shareholderSell27,962$2.20$61,516.406,270,046View SEC Filing  
1/6/2014Cooper Collinsmajor shareholderSell62,038$2.35$145,789.306,298,008View SEC Filing  
12/6/2013Cooper Collinsmajor shareholderSell37,452$2.31$86,514.126,360,046View SEC Filing  
12/4/2013Cooper Collinsmajor shareholderSell52,548$2.44$128,217.126,397,498View SEC Filing  
11/5/2013Cooper C CollinsMajor ShareholderSell90,000$2.01$180,900.00View SEC Filing  
10/8/2013Cooper Collinsmajor shareholderSell23,364$2.47$57,709.086,540,046View SEC Filing  
10/9/2012Michael Cooper PearceDirectorSell1,288$8.00$10,304.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pernix Therapeutics (NASDAQ PTX) News Headlines

Source:
DateHeadline
Contrasting Aptevo Therapeutics (APVO) & Pernix Therapeutics (PTX)Contrasting Aptevo Therapeutics (APVO) & Pernix Therapeutics (PTX)
www.americanbankingnews.com - April 23 at 1:42 PM
One Thing To Consider Before Buying Pernix Therapeutics Holdings Inc (NASDAQ:PTX)One Thing To Consider Before Buying Pernix Therapeutics Holdings Inc (NASDAQ:PTX)
finance.yahoo.com - April 11 at 5:01 PM
Form 4/A PERNIX THERAPEUTICS HOLD For: Jan 05 Filed by: Pina KennethForm 4/A PERNIX THERAPEUTICS HOLD For: Jan 05 Filed by: Pina Kenneth
www.streetinsider.com - April 10 at 5:02 PM
Active-Investors: Wired News - Amarins REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACEActive-Investors: Wired News - Amarin's REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE
www.finanznachrichten.de - April 6 at 9:03 AM
Pernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek® 20 mgPernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek® 20 mg
finance.yahoo.com - March 27 at 9:08 AM
Why Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX) Ownership Structure Is ImportantWhy Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX) Ownership Structure Is Important
finance.yahoo.com - March 20 at 9:04 AM
Edited Transcript of PTX earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of PTX earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:49 AM
Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 10 at 5:55 PM
Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 ... - NasdaqPernix Therapeutics Reports Fourth Quarter and Full Year 2017 ... - Nasdaq
www.nasdaq.com - March 9 at 9:08 AM
Earnings Reaction History: Pernix Therapeutics Holdings, Inc., 50.0% Follow-Through Indicator, 12.1% Sensitive - NasdaqEarnings Reaction History: Pernix Therapeutics Holdings, Inc., 50.0% Follow-Through Indicator, 12.1% Sensitive - Nasdaq
www.nasdaq.com - March 9 at 9:08 AM
Pernix Therapeutics reports 4Q lossPernix Therapeutics reports 4Q loss
www.cnbc.com - March 8 at 6:03 PM
Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsPernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 6:03 PM
Comparing Pernix Therapeutics (PTX) & Akcea Therapeutics (AKCA)Comparing Pernix Therapeutics (PTX) & Akcea Therapeutics (AKCA)
www.americanbankingnews.com - March 8 at 4:13 PM
Head to Head Analysis: Pernix Therapeutics (PTX) & Collegium Pharmaceutical (COLL)Head to Head Analysis: Pernix Therapeutics (PTX) & Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - March 2 at 1:16 AM
Pernix Therapeutics (PTX) to Release Earnings on ThursdayPernix Therapeutics (PTX) to Release Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM
Where Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Stands In Terms Of Earnings Growth Against Its IndustryWhere Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - February 27 at 5:29 PM
Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8
finance.yahoo.com - February 22 at 5:15 PM
BRIEF-Pernix Announces Launch Of Authorized Generic Of TreximetBRIEF-Pernix Announces Launch Of Authorized Generic Of Treximet
www.reuters.com - February 16 at 4:59 PM
Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven PharmaceuticalsPernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals
finance.yahoo.com - February 16 at 4:59 PM
Head to Head Analysis: Amicus Therapeutics (FOLD) vs. Pernix Therapeutics (PTX)Head to Head Analysis: Amicus Therapeutics (FOLD) vs. Pernix Therapeutics (PTX)
www.americanbankingnews.com - February 9 at 5:10 AM
Pernix Announces Appointment of Lead Independent Director and Key Management Team PromotionPernix Announces Appointment of Lead Independent Director and Key Management Team Promotion
finance.yahoo.com - February 7 at 9:41 AM
Reviewing Celsius (CELH) and Pernix Therapeutics (PTX)Reviewing Celsius (CELH) and Pernix Therapeutics (PTX)
www.americanbankingnews.com - February 5 at 11:14 PM
Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ERPernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER
finance.yahoo.com - January 29 at 9:46 AM
BRIEF-Pernix Therapeutics Will Reduce Workforce By 41 EmployeesBRIEF-Pernix Therapeutics Will Reduce Workforce By 41 Employees
www.reuters.com - January 5 at 10:29 AM
Pernix Announces Reorganization of Sales Force to Focus on Zohydro® ER with BeadTek™ and Silenor®Pernix Announces Reorganization of Sales Force to Focus on Zohydro® ER with BeadTek™ and Silenor®
finance.yahoo.com - January 5 at 10:29 AM
Achaogens NDA for Plazomicin Gets Priority Review From FDA ... - NasdaqAchaogen's NDA for Plazomicin Gets Priority Review From FDA ... - Nasdaq
www.nasdaq.com - January 3 at 4:39 PM
Achaogens NDA for Plazomicin Gets Priority Review From FDAAchaogen's NDA for Plazomicin Gets Priority Review From FDA
www.zacks.com - January 3 at 9:34 AM
Analyzing Celgene (CELG) & Pernix Therapeutics (PTX)Analyzing Celgene (CELG) & Pernix Therapeutics (PTX)
www.americanbankingnews.com - January 2 at 1:20 PM
Head-To-Head Survey: AMAG Pharmaceuticals (AMAG) and Pernix Therapeutics (PTX)Head-To-Head Survey: AMAG Pharmaceuticals (AMAG) and Pernix Therapeutics (PTX)
www.americanbankingnews.com - January 1 at 11:24 AM
ETFs with exposure to Pernix Therapeutics Holdings, Inc. : December 19, 2017ETFs with exposure to Pernix Therapeutics Holdings, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 4:34 PM
Analyzing Pernix Therapeutics (PTX) and Concordia International (CXRX)Analyzing Pernix Therapeutics (PTX) and Concordia International (CXRX)
www.americanbankingnews.com - December 13 at 3:53 PM
ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 29, 2017ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 4:48 PM
Pernix Therapeutics (PTX) vs. BioLife Solutions (BLFS) Financial ReviewPernix Therapeutics (PTX) vs. BioLife Solutions (BLFS) Financial Review
www.americanbankingnews.com - November 26 at 5:50 PM
BRIEF-Pernix Therapeutics files for mixed shelf offering of up to $150 mlnBRIEF-Pernix Therapeutics files for mixed shelf offering of up to $150 mln
www.reuters.com - November 23 at 7:51 AM
Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 14 at 7:02 AM
Platinex Signs LOI to Acquire Interest in Cannabis-Infused Edible Brand and Co-Packing Facility in Oregon, Raising $600,000 in Private Placement - Video Hosted on InvestmentPitch.comPlatinex Signs LOI to Acquire Interest in Cannabis-Infused Edible Brand and Co-Packing Facility in Oregon, Raising $600,000 in Private Placement - Video Hosted on InvestmentPitch.com
finance.yahoo.com - November 12 at 11:58 AM
Pernix Therapeutics Holdings (PTX) and Akorn (AKRX) Financial AnalysisPernix Therapeutics Holdings (PTX) and Akorn (AKRX) Financial Analysis
www.americanbankingnews.com - November 10 at 2:14 PM
Pernix Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Pernix Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 11:59 AM
Pernix Therapeutics Holdings, Inc. to Host Earnings CallPernix Therapeutics Holdings, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 11:58 AM
ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 7, 2017ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 7, 2017
finance.yahoo.com - November 9 at 11:58 AM
Pernix Therapeutics Reports Third Quarter 2017 Financial ResultsPernix Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 11:58 AM
Edited Transcript of PTX earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of PTX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 11:58 AM
BRIEF-Pernix Therapeutics announces sale of non-core productBRIEF-Pernix Therapeutics announces sale of non-core product
www.reuters.com - November 7 at 9:09 AM
Pernix Therapeutics (PTX) Sells Non-Core Product for $2MPernix Therapeutics (PTX) Sells Non-Core Product for $2M
www.streetinsider.com - November 7 at 9:09 AM
Pernix Therapeutics Announces Sale of Non-Core ProductPernix Therapeutics Announces Sale of Non-Core Product
finance.yahoo.com - November 7 at 9:09 AM
Who Are The Largest Shareholders In Pernix Therapeutics Holdings Inc (PTX)?Who Are The Largest Shareholders In Pernix Therapeutics Holdings Inc (PTX)?
finance.yahoo.com - November 1 at 7:48 AM
Pernix Therapeutics Holdings, Inc. (PTX) Scheduled to Post Earnings on WednesdayPernix Therapeutics Holdings, Inc. (PTX) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 1 at 1:44 AM
Pernix Therapeutics to Report Third Quarter 2017 Financial Results on Tuesday, November 7Pernix Therapeutics to Report Third Quarter 2017 Financial Results on Tuesday, November 7
finance.yahoo.com - October 27 at 11:55 AM
Analyzing Pernix Therapeutics Holdings (PTX) and CoLucid Pharmaceuticals (CLCD)Analyzing Pernix Therapeutics Holdings (PTX) and CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - October 25 at 2:54 PM
BRIEF-Pernix Therapeutics says CFO and president Graham Miao resignsBRIEF-Pernix Therapeutics says CFO and president Graham Miao resigns
www.reuters.com - October 18 at 2:22 AM

SEC Filings

Pernix Therapeutics (NASDAQ:PTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pernix Therapeutics (NASDAQ:PTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pernix Therapeutics (NASDAQ PTX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.